QPPV.COM KNOWLEDGE ASSESSMENT

EU Pharmacovigilance Inspection Findings: Lifecycle Management and Continuity of Pharmacovigilance Controls

Test your understanding of the concepts covered by EU Pharmacovigilance Inspection Findings: Lifecycle Management and Continuity of Pharmacovigilance Controls.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A company transfers a portfolio but does not inventory ongoing signals, studies and regulatory commitments. What weakness does this most directly indicate?

A failure to distinguish legal ownership from pharmacovigilance consequences An excessive focus on post-transition monitoring A requirement to replace all existing vendors A problem limited to product labelling

Question 2 of 10 What should a safety-database migration assessment emphasize beyond technical functionality?

Only whether users can log in to the new database Data integrity, reconciliation, access controls, deviation management and continued usability of historical information Whether the new database has the same visual design as the old one Whether all legacy users are given permanent access to both systems

Question 3 of 10 Which comparison would most directly test whether contractual responsibilities match actual pharmacovigilance operations?

Contract or safety-data-exchange agreement compared with the actual workflow and transaction Marketing budget compared with employee headcount Product artwork compared with the training calendar Regulatory approval date compared with office relocation date

Question 4 of 10 Why are training-completion records insufficient on their own to demonstrate transition readiness?

Training records are never relevant to pharmacovigilance inspections Completion shows participation but not necessarily the ability to perform the revised safety-critical process effectively Personnel should not be trained until after implementation Readiness is demonstrated only by revising the PSMF

Question 5 of 10 What is the primary reason open cases require specific transition planning?

Open cases are no longer subject to follow-up after a transfer Open cases continue to evolve and may generate follow-up, reassessment or additional reporting after responsibility changes Open cases can always be closed and recreated in the receiving system Only cases involving non-serious events require transfer controls

Question 6 of 10 Which statement best captures the relationship between lifecycle management and CAPA effectiveness?

Correcting one affected case always demonstrates effective CAPA CAPA should address the transition mechanism and test whether the relevant preventive control works across potentially affected scope CAPA is unnecessary if the transition project was formally closed Effectiveness verification should assess only whether an action-list item was marked complete

Question 7 of 10 An organisation divests a product and immediately removes all access to the former safety database. What is the principal inspection risk?

The organisation may be unable to retrieve or interpret historical evidence supporting past pharmacovigilance activities The organisation has necessarily violated a requirement to retain every system indefinitely The divested product can no longer be subject to any pharmacovigilance obligation The receiving organisation must use the former company's database permanently

Question 8 of 10 Which finding pattern is best described as an incomplete impact assessment?

The organisation assessed only the commercial or legal event and did not evaluate affected products, activities, systems, vendors or records The organisation performed risk-based post-transition monitoring The organisation documented a justified difference between the plan and implementation The organisation preserved historical records and tested their retrieval

Question 9 of 10 Which statement best describes the relationship between a PSMF update and transition effectiveness?

A revised PSMF proves that the operational transition was effective The PSMF is irrelevant during organisational change if contracts are current The PSMF should accurately reflect the implemented system, but its revision alone does not demonstrate effective transition control The PSMF should describe the planned future system even if it is not yet implemented

Question 10 of 10 Why are multiple dates relevant to inspection assessment of a lifecycle transition?

Only the date of system cutover has regulatory relevance Legal completion, regulatory approval, operational handover and assumption of full responsibility may occur at different times Different dates are used only for financial reporting purposes The earliest date always determines which organisation was responsible for every activity

QPPV.com

EU Pharmacovigilance Inspection Findings: Lifecycle Management and Continuity of Pharmacovigilance Controls

Cookie Settings